Physician profile
Miles Sumner
NPI 1881939106
$8,935.33
in general payments reported to CMS, 2019-2025
31 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,415 · 2022: $1,344 · 2023: $5,406 · 2024: $651 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,708 · Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,708.33 |
| Food and Beverage | $1,467.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $4,708.33 | 2023 | Auryon Laser System 100-120 Vac |
| Organogenesis INC. | $561.94 | 2021-2025 | Affinity, Puraply Wound Matrix, Apligraf |
| Gilead Sciences, INC. | $338.26 | 2021-2022 | |
| Abbvie INC. | $321.88 | 2021-2022 | |
| Genentech USA, INC. | $288.49 | 2021 | |
| Horizon Therapeutics Plc | $238.97 | 2021 | |
| Edwards Lifesciences Corporation | $236.84 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $194.41 | 2021-2022 | |
| Convatec INC. | $179.88 | 2023-2024 | |
| Abbott Laboratories | $143.69 | 2022-2023 | Octrode |
| Solventum Corporation | $136.49 | 2024-2025 | Activ.A.C., Promogran Prisma |
| Next Science LLC | $134.36 | 2023 | Xperience, Surgx, Blastx |
| Medtronic, INC. | $132.84 | 2024 | In.Pact Admiral, Venaseal |
| Bayer Healthcare Pharmaceuticals INC. | $125.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $124.99 | 2022 | |
| Novo Nordisk INC | $124.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.82 | 2021 | |
| Tactile Systems Technology INC | $119.31 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Philips North America LLC | $99.08 | 2023 | |
| Integra Lifesciences Corporation | $84.92 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Paratek Pharmaceuticals, INC. | $79.01 | 2023-2025 | Nuzyra |
| Celgene Corporation | $78.47 | 2021 | |
| Janssen Biotech, INC. | $60.13 | 2021-2022 | |
| Advanced Oxygen Therapy INC. | $34.58 | 2023-2025 | Topical Oxygen Chamber For Extremities, Topical Oxygen Chamber For Extremities |
| Bsn Medical INC | $33.33 | 2024-2025 | |
| Smith+Nephew, INC. | $31.43 | 2023 | Grafix Pl, Grafix, Oasis |
| Urgo Medical North America, LLC | $27.75 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Musculoskeletal Transplant Foundation INC. | $18.35 | 2023 | |
| Kci USA, INC. | $16.04 | 2023 | Activ.A.C. |
| Merck Sharp & Dohme LLC | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.